COMMUNIQUÉS West-GlobeNewswire

Resverlogix Proudly Announces Funding for Phase 2 Trial Evaluating Apabetalone in Pulmonary Arterial Hypertension Led by Quebec Heart and Lung Institute – Laval University Researcher
18/03/2019
Resverlogix also advances its Fabry Disease indication data and planning CALGARY, Alberta, March 18, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announced the advancement [...]
BioPorto A/S - Annual General Meeting
18/03/2019
March 18, 2019 Announcement no. 4 BioPorto A/S - Annual General Meeting Today, BioPorto A/S held its Annual General Meeting where the shareholders took note of the report on the Company’s activities and adopted the 2018 [...]
HPV Vaccine Mandate Ill-Advised, States Association of American Physicians and Surgeons (AAPS)
18/03/2019
TUCSON, Ariz., March 18, 2019 (GLOBE NEWSWIRE) -- Connecticut is considering legislation to end the religious exemption for mandated vaccines and to mandate human papillomavirus (HPV) vaccines for pre-teens, reports the [...]
Oasmia announces a prospectus regarding admission to trading of new shares
18/03/2019
Oasmia Pharmaceutical AB (publ) (“Oasmia” or the ”Company”) has prepared a prospectus regarding the admission to trading of the 22,948,535 shares in the Company that were issued in the directed issue which was announced [...]
BioAegis Therapeutics Completes Enrollment in its Phase 1b/2a Dose-Ranging Safety Study of Recombinant Plasma Gelsolin for Community-Acquired Pneumonia
18/03/2019
MORRISTOWN, N.J., March 18, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announced that it has completed patient enrollment in its Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN) as adjunctive therapy [...]
Novo Nordisk A/S - Share repurchase programme
18/03/2019
Bagsværd, Denmark, 18 March 2019 - On 1 February 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 [...]
Coherus BioSciences Receives Transitional Pass-Through Status from CMS
18/03/2019
REDWOOD CITY, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that the Centers for Medicare and Medicaid Services (CMS) approved UDENYCA™ (pegfilgrastim-cbqv) [...]
Coherus BioSciences Appoints Thomas Fitzpatrick Chief Legal Officer
18/03/2019
REDWOOD CITY, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced the addition of Thomas Fitzpatrick as its Chief Legal Officer. Mr. Fitzpatrick brings more than 20 years [...]
Eidos Therapeutics Announces Publication in the Journal of the American College of Cardiology (JACC) and Presentation at American College of Cardiology (ACC) Scientific Sessions
18/03/2019
AG10 demonstrated equivalent, near-complete stabilization of TTR in wild-type and mutant subjects with TTR amyloid cardiomyopathy (ATTR-CM). AG10 treatment normalized serum TTR levels, a prognostic indicator of survival [...]
XACT Robotics expands its patents portfolio to include the use of ultrasound
18/03/2019
CAESAREA, Israel, March 18, 2019 (GLOBE NEWSWIRE) -- XACT Robotics Ltd. today announced that the European Patent Office (EPO) will grant a patent expanding the Company’s patent portfolio to include the use of its [...]
Zenith Epigenetics Announces U.S. FDA Clearance of Investigational New Drug Application for ZEN-3694 in TNBC Program
18/03/2019
Pfizer / Zenith TNBC program collaboration on target to dose first patient in April 2019 Phase 2 mCRPC program and clinical data to be presented at AACR CALGARY, Alberta, March 18, 2019 (GLOBE NEWSWIRE) -- Zenith [...]
Adverum Biotechnologies to Participate in Upcoming Conferences
18/03/2019
MENLO PARK, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the [...]
Aptevo Therapeutics Reports 2018 Financial Results and Provides Business Update
18/03/2019
Achieves Record Annual IXINITY ® Net Revenue of $23.1 Million Representing 111% Increase Over 2017 Advances APVO436 Into Phase 1/1b Clinical Trial for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic [...]
Innovate Biopharmaceuticals Announces Entry Into Securities Purchase Agreement to Fund Initiation of the First Phase 3 Celiac Disease Clinical Trial
18/03/2019
RALEIGH, N.C., March 18, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (“Innovate” or the “Company”) (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel autoimmune and [...]
Share buy-back week 11/2019
18/03/2019
Announcement 18 March 2019 Coloplast – transactions in connection with share buy-back programme As mentioned in Announcement No. 2/2019 Coloplast has initiated the second part of the share buy-back programme totalling [...]
UPDATE: Tauriga Sciences, Inc. Receives Initial $54,000 Tauri-Gum Purchase Order from Major New York City Based Distributor
18/03/2019
NEW YORK, NY, March 18, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Tauriga Sciences, Inc. (OTCQB: TAUG ) (“Tauriga” or the “Company”), engaged in building its business through the development, distribution, and [...]
Identification of Phosphodiesterease 3A Polymorphism With Potential to Increase Effectiveness of PDE3 Inhibitors Published in the Journal of the American College of Cardiology
18/03/2019
WESTMINSTER, Colo., March 18, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for [...]
Yield Growth Doubles Down on Hemp Root Oil -- CFN Media
18/03/2019
SEATTLE, March 18, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an [...]
Minerva Neurosciences to Host Webcast Event on Schizophrenia
18/03/2019
Decision Resources Group to provide review of the disease landscape and forecast Key opinion leader to discuss negative symptoms in schizophrenia Minerva to outline roluperidone’s potential position within the disease [...]

Pages